戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 nesis of autoimmunity and lymphomagenesis of autoimmune lymphoproliferative syndrome.
2 tients with systemic lupus erythematosus and autoimmune lymphoproliferative syndrome.
3 e classified the disease as a variant of the autoimmune lymphoproliferative syndrome.
4  disease to differentiate this disorder from autoimmune lymphoproliferative syndrome.
5 th Fas-induced lymphocyte apoptosis in human autoimmune lymphoproliferative syndrome.
6 ade FADD a candidate susceptibility gene for autoimmune lymphoproliferative syndrome.
7 ation and autoimmune cytopenias characterise autoimmune lymphoproliferative syndrome.
8 cause severe immunodeficiency in addition to autoimmune lymphoproliferative syndrome(4-6).
9 of mTOR activation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease drive
10                   All children (N = 12) with autoimmune lymphoproliferative syndrome (ALPS) achieved
11                                          The autoimmune lymphoproliferative syndrome (ALPS) affords n
12 Fas) receptor occur in most individuals with autoimmune lymphoproliferative syndrome (ALPS) and domin
13                                Patients with autoimmune lymphoproliferative syndrome (ALPS) and syste
14 ts in lymphocyte apoptosis that underlie the autoimmune lymphoproliferative syndrome (ALPS) are usual
15                                              Autoimmune lymphoproliferative syndrome (ALPS) caused by
16                                              Autoimmune lymphoproliferative syndrome (ALPS) in humans
17 tions of the Fas gene can result in a severe autoimmune lymphoproliferative syndrome (ALPS) in humans
18                                              Autoimmune lymphoproliferative syndrome (ALPS) is a diso
19                                              Autoimmune lymphoproliferative syndrome (ALPS) is a diso
20                                              Autoimmune lymphoproliferative syndrome (ALPS) is a diso
21                                              Autoimmune lymphoproliferative syndrome (ALPS) is a diso
22                                              Autoimmune lymphoproliferative syndrome (ALPS) is a gene
23                                              Autoimmune lymphoproliferative syndrome (ALPS) is a huma
24                                              Autoimmune lymphoproliferative syndrome (ALPS) is a huma
25                                              Autoimmune lymphoproliferative syndrome (ALPS) is a huma
26                                          The autoimmune lymphoproliferative syndrome (ALPS) is a noni
27                                              Autoimmune lymphoproliferative syndrome (ALPS) is a rare
28                                              Autoimmune Lymphoproliferative Syndrome (ALPS) is a rece
29                                              Autoimmune lymphoproliferative syndrome (ALPS) is an inh
30                                              Autoimmune lymphoproliferative syndrome (ALPS) is caused
31                                              Autoimmune lymphoproliferative syndrome (ALPS) is charac
32                                          The autoimmune lymphoproliferative syndrome (ALPS) is charac
33                                              Autoimmune lymphoproliferative syndrome (ALPS) is charac
34                           The human disease, Autoimmune Lymphoproliferative Syndrome (ALPS) is due to
35                                              Autoimmune lymphoproliferative syndrome (ALPS) is marked
36                                              Autoimmune lymphoproliferative syndrome (ALPS) is the mo
37 , immunological, and clinical aspects of the autoimmune lymphoproliferative syndrome (ALPS) met in Be
38 ice et al document a 20-year experience with autoimmune lymphoproliferative syndrome (ALPS) patients
39  T cells with a phenotype similar to that in autoimmune lymphoproliferative syndrome (ALPS) patients.
40                                              Autoimmune lymphoproliferative syndrome (ALPS) presents
41                                              Autoimmune lymphoproliferative syndrome (ALPS) represent
42 ressing Fas mutations from patients with the autoimmune lymphoproliferative syndrome (ALPS) reveals t
43                                              Autoimmune lymphoproliferative syndrome (ALPS) type Ia i
44             We report here two kindreds with autoimmune lymphoproliferative syndrome (ALPS) type II,
45 al. explore somatic changes in patients with autoimmune lymphoproliferative syndrome (ALPS), a congen
46  ligand or caspase-10 underlie most cases of autoimmune lymphoproliferative syndrome (ALPS), a human
47                                A hallmark of autoimmune lymphoproliferative syndrome (ALPS), caused b
48 ototype for human apoptosis disorders is the autoimmune lymphoproliferative syndrome (ALPS), which is
49 nd show remarkable efficacy in children with autoimmune lymphoproliferative syndrome (ALPS).
50 uble-negative T cells (DNT) is a hallmark of autoimmune lymphoproliferative syndrome (ALPS).
51 nd cause recessively or dominantly inherited autoimmune lymphoproliferative syndrome (ALPS).
52 rkers help identify FAS mutant patients with autoimmune lymphoproliferative syndrome (ALPS).
53      Lymphomas were studied in kindreds with autoimmune lymphoproliferative syndrome (ALPS; Canale-Sm
54 oss-of-function FAS or FASLG mutations cause autoimmune-lymphoproliferative syndrome (ALPS) character
55                                           In autoimmune/lymphoproliferative syndrome (ALPS), defectiv
56 d exome sequencing in a patient with NDM and autoimmune lymphoproliferative syndrome and his unrelate
57  have revealed an ever-expanding spectrum of autoimmune lymphoproliferative syndrome and its major co
58 Gadd45gamma spontaneously developed signs of autoimmune lymphoproliferative syndrome and systemic lup
59 sociated with inherited human mutations: the autoimmune lymphoproliferative syndrome and the caspase-
60  mycobacterial diseases, Hyper-IgM syndrome, autoimmune lymphoproliferative syndrome, and GATA-2 defi
61 el homozygous mutation in ITK presented with autoimmune lymphoproliferative syndrome, and had impaire
62 with idiopathic CD4 lymphopenia, people with autoimmune lymphoproliferative syndrome, and healthy vol
63                                              Autoimmune lymphoproliferative syndrome arises early in
64                                              Autoimmune lymphoproliferative syndrome biomarkers were
65 n humans, fas mutations result in a familial autoimmune lymphoproliferative syndrome, but defects in
66            In lpr/lpr mice and children with autoimmune lymphoproliferative syndrome, defective apopt
67                                           In autoimmune lymphoproliferative syndrome, defective lymph
68       We recruited 431 children referred for autoimmune lymphoproliferative syndrome evaluation, of w
69 tosus, common variable immunodeficiency, and autoimmune lymphoproliferative syndromes, hemophagocytic
70 for caspase-10, previously implicated in the autoimmune lymphoproliferative syndrome, in death recept
71                                Most cases of autoimmune lymphoproliferative syndrome involve heterozy
72 haring these manifestations have been termed autoimmune lymphoproliferative syndrome-like diseases, a
73 ed-coil domain of STAT5B that presented with autoimmune lymphoproliferative syndrome-like features.
74                                 Here, we use autoimmune lymphoproliferative syndrome to identify a po
75     After biomarker and genetic assessments, autoimmune lymphoproliferative syndrome was diagnosed in
76 eceptor FAS(1,2) or its ligand FASL(3) cause autoimmune lymphoproliferative syndrome, whereas mutatio
77 d for patients with biomarkers indicative of autoimmune lymphoproliferative syndrome, while IEI panel
78 inically significant immunodeficiency and an autoimmune lymphoproliferative syndrome with marked pred
79  suggests potential treatments for lupus and autoimmune lymphoproliferative syndrome, without comprom